Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor
given orally to patients with relapsed or refractory PTCL or CTCL.
Approximately 60 patients with relapsed or refractory PTCL or CTCL who meet the eligibility
criteria and have none of the exclusion criteria will be enrolled to receive selinexor until
either disease progression or intolerance has occurred.